Hemophilia refers to an inherited
genetic blood disorder which affects the ability of the blood to clot due to
the lack of a specific protein required for blood clotting. As per the analysis
of Market Research Future (MRFR), the global hemophilia treatment market is
likely to post a CAGR of 6.10% over the forecast period of 2018-2023. The
global hemophilia treatment market was valued at USD 11,257.21 in 2017 and is
due to reach a valuation of USD 16,059.17 by the end of 2023.
The prevalence of hemophilia is found
to be high across the globe, and it is in the backdrop of such high prevalence
of hemophilia, the global hemophilia
treatment market is expanding steadily. The World Federation of Hemophilia
estimates the number of people suffering from hemophilia in the US to be close
to 17,000.
An outlay of massive amounts by
biotechnology companies and high government support for R&D activities has
resulted in significant developments in recent years. Recombinant products have
emerged as an alternative to plasma-derived products and consumers have
demonstrated an increased inclination towards the use of recombinant products
which can also be credited for the growth of the global hemophilia treatment
market. Recombinant products, is derived from genetically engineered cells at
are zero risks of contamination.
On the downside, the market growth
might be deterred by the high costs associated with hemophilia treatment which
restricts the growth of the market in cost-sensitive markets. Hemophilia
treatment involves a variety of technologically high-end products which limits
the patient pool opting for treatment.
Segmentation
The global hemophilia treatment
market has been segmented based on type, treatment type, and end user.
By type, the global hemophilia
treatment market has been segmented into hemophilia A, hemophilia B, and
hemophilia C. The hemophilia A segment is the largest segment and is expected
to reach a valuation of USD 12,697.99 at a CAGR of 6.23% by the end of the
forecast period.
By treatment type, the global
hemophilia treatment market has been segmented into Plasma-derived coagulation
factor concentrate, Recombinant coagulation factor concentrates, Desmopressin,
Antifibrinolytic agents, and Gene Therapy. The recombinant coagulation factor
concentrates segment is likely to expand at the highest CAGR of 7.01% over the
forecast period.
By end user, the global hemophilia
treatment market has been segmented into hospitals & clinics, research
organizations, and others. The hospitals & clinics segment accounted for
the largest share of USD 7594.66 in 2017 and is also anticipated to showcase
the fastest growth over the forecast period.
Regional Analysis
Geographically, the global hemophilia
treatment market has been segmented into the Americas, Europe, Asia Pacific
(APAC), and the Middle East & Africa (MEA). The Americas account for the
lion's share of the global hemophilia treatment market and is likely to
maintain its lead over the forecast period. The growth of the Americas market
can be attributed to the high occurrence of the disorder in the region coupled
with growing expenditure on the healthcare sector. The presence of an
established healthcare sector and towering support for R&D activities acts
as a plus for the market growth.
Europe holds the second largest share
of the global hemophilia treatment market and exhibits similar growth pattern
as that of the Americas. The Europe hemophilia treatment market is driven by
high government support for research and development to develop advanced
medical therapies.
APAC is poised to showcase the
highest growth rate of 8.38% over the forecast period. Prolific improvement in
the healthcare sector coupled with high demand for advanced treatment options
stimulates the growth of the APAC hemophilia treatment market. The presence of
a large patient pool is also a co0ntributing factor.
Competitive
Landscape
The key players in the global
hemophilia treatment market include F.Hoffmann-La Roche Ltd, Bayer AG, Baxter,
Pfizer Inc, Sanofi, Novo Nordisk A/S, Shire, Kedrion, CSL Behring, Octapharma,
Swedish Orphan Biovitrum AB, and Grifols International S.A.
Read
Complete Report @ https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum
quality market research and intelligence services to our clients. Our market
research studies by Components, Application, Logistics and market players for
global, regional, and country level market segments, enable our clients to see
more, know more, and do more, which help to answer all their most important
questions.
In order to stay updated with technology and work process of
the industry, MRFR often plans & conducts meet with the industry experts
and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment